Navigation Links
Registry unveils 'real-world' data on novel excel stent
Date:3/31/2008

CHICAGO, Ill. (March 31, 2008) Real-world use of a novel drug-eluting stent coated with a biodegradable polymer is associated with good clinical outcomes, according to one-year data from a large international registry. Results of the CREATE study, which focused on the sirolimus-eluting Excel stent, are being reported today in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the American College of Cardiology (ACC).

For the study, Yaling Han, MD, Shenyang Northern Hospital, Shenyang, China, and colleagues recruited a total of 2,077 patients from 59 medical centers in four countries. All had stenting with the Excel stent, a novel device with a biodegradable polymer coating. Of these, 369 (17.8 percent) underwent primary stenting within 24 hours of having a heart attack.

After stenting, all patients were prescribed both clopidogrel and aspirin for six months to inhibit the action of platelets in the blood. Anti-platelet medications prevent the development of unwanted blood clots within the stent, or stent thrombosis, a serious complication that can cause heart attack or even death. On average, patients continued to take clopidogrel for 199 days.

Twelve-month follow-up data were available for 2,060 patients (99.2 percent). After 12 months, the overall rate of major cardiovascular complications was 2.77 percent, including cardiac death in 23 patients (1.12 percent), heart attack in 8 patients (0.39 percent), and repeat coronary procedure in 32 patients (1.55 percent). Death from any cause occurred in 34 patients (1.64 percent), including 11 noncardiac deaths. Overall, thrombotic complications occurred in 16 patients (0.78 percent), including six definite cases, five pro
'/>"/>

Contact: Kathy Boyd David
pr@scai.org
717-422-1181
Weber Shandwick Worldwide
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
2. REACH Registry Highlights That Patients With Peripheral Arterial Disease (PAD) Suffer High Rates of Heart Attack, Stroke, Hospitalization, and Death
3. Establishment of Topps Meat Recall Registry for Victims of E. Coli Poisoning
4. E. Coli Registry Expanded for Victims of E. Coli Poisoning from Cargill Ground Beef
5. 5,000 Patients Treated With OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Now Enrolled in Real-Life Use Global Registry
6. Matrix registry probes adherence to clopidogrel at 1 year
7. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
8. Wellcorps International Unveils New Nutritional Supplements
9. The Village Company Unveils Natural Bath and Body Solutions for Everyday Ailments
10. Rice unveils $100 million initiative for world health technology
11. Medco Unveils Three New Medicare Prescription Drug Plan Options for 2008 to Provide Seniors More Choice, Better Value and Specialist Pharmacists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Dennis Thompson HealthDay Reporter ... people with depression are more likely to develop dementia, but ... the relationship between the two. Specifically, they haven,t been ... works -- does depression help bring on dementia, or does ... published online July 30 in the journal Neurology ...
(Date:7/30/2014)... drug to treat malaria, is now widespread throughout ... ( P. falciparum ) parasites that cause the ... mutation in the parasites. However, a six-day course ... three-day coursehas proved highly effective in treating drug-resistant ... the New England Journal of Medicine . ...
(Date:7/30/2014)... Mozes HealthDay Reporter WEDNESDAY, ... help their preschooler shed excess pounds may want to team ... parents joined them in a supervised behavioral modification program gained ... traditional child-only program (an average difference of about four pounds ... 15 pounds over two years, according to the study. ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 SF Cable, ... at the lowest prices on the internet with guaranteed ... in two lengths and two colors. These lightning cords ... , The high quality SF Cable Lightning ... with digital signal delivering faster charging and syncing. Compatible ...
(Date:7/30/2014)... Lexington, MA (PRWEB) July 30, 2014 ... provider of authentication, access management and secure communications ... Imprivata OneSign ® is the most widely ... using McKesson Paragon or Horizon electronic medical records ... (an increase of about 11 percent in the ...
Breaking Medicine News(10 mins):Health News:Scientists Shed Light on Link Between Depression, Dementia 2Health News:Scientists Shed Light on Link Between Depression, Dementia 3Health News:Resistance to key malaria drug spreading at alarming rate in Southeast Asia 2Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 2Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 3Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 4Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2
... Toronto Stock Exchange Symbol: CYT, MONTREAL, May ... cryotherapy products to treat cardiac,arrhythmias, today announced financial results ... Selected Second Quarter Financial and Operational Highlights:, - ... $10.2 million or a 37.6% ...
... N.Y., May 12 Gentiva Health,Services, Inc. (Nasdaq: ... services, announced today that it is scheduled to,present from ... 2008 at the 2008,Citi Investment Research Global Health Care ... available to the public via a live audio web,cast, ...
... IQ more likely the younger a child is at diagnosis, study ... 5 percent of people with multiple sclerosis are diagnosed when they,re ... function, causing memory and attention problems, and possibly low IQ scores. ... of diagnosis, the more likely he or she is to have ...
... even harm cognitive function , , MONDAY, May 12 (HealthDay News) ... daily use of two popular pain-relieving drugs, Celebrex and naproxen, ... history of Alzheimer,s disease. , In fact, naproxen, which goes ... a deleterious effect on cognitive function, the study found. ...
... than 2,000,hospital employees, patients and others concerned about the ... State House today in the "Care,Today, Gone Tomorrow" rally ... Toting signs that read "Some Cuts Never Heal" ... and state lawmakers to restore,the $143 million in charity ...
... Damir Matic, a scientist with Lawson Health Research Institute in ... performed throughout North America and around the world. Matic ... close the gum tissue of cleft palate patients. His research ... is older. , Matic is a craniofacial/plastic surgeon at London ...
Cached Medicine News:Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 2Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 3Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 4Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 5Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 6Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 7Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 8Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 9Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 10Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 11Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 12Health News:Gentiva(R) Health Services to Present May 21 at 2008 Citi Investment Research Global Health Care Conference in New York 2Health News:Gentiva(R) Health Services to Present May 21 at 2008 Citi Investment Research Global Health Care Conference in New York 3Health News:Multiple Sclerosis Affects Children's Cognitive Skills 2Health News:Multiple Sclerosis Affects Children's Cognitive Skills 3Health News:Celebrex, Naproxen Won't Prevent Mental Decline 2Health News:Celebrex, Naproxen Won't Prevent Mental Decline 3Health News:Crowd Rallies to Protest Hospital Cuts 2Health News:Crowd Rallies to Protest Hospital Cuts 3Health News:Crowd Rallies to Protest Hospital Cuts 4Health News:Research shows timing improves cleft palate surgery 2
(Date:7/30/2014)... 2014 /PRNewswire-iReach/ -- Transluminal Technologies LLC, a ... has announced today that they have received CE ... Device. Velox CD™ provides a safe and predictable ... procedures. The single size velox CD™ is indicated ... 5F to 8F.  Velox CD™ utilizes ...
(Date:7/30/2014)... 2014  InnoPharma, Inc. today announced the first generic ... of Zyprexa® injection), in Canada.  Olanzapine is indicated for ... patients with schizophrenia or bipolar I mania. ... has entered into an agreement with Sandoz Canada Inc., ... use, sell, market and distribute Olanzapine Injection in ...
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN ) and Sanofi (EURONEXT: SAN and ... new Phase 3 ODYSSEY trials of alirocumab in people ... greater percent reduction from baseline in low-density lipoprotein cholesterol ... comparator.  Alirocumab is an investigational monoclonal antibody targeting PCSK9 ...
Breaking Medicine Technology:Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8
... WIXOM, Mich., Sept. 19 Rockwell Medical,Technologies, ... innovative manufacturer and,developer of concentrates and specialty ... announced today that it has commenced,enrollment in ... Ferric,Pyrophosphate (SFP), a physiological iron-maintenance therapy drug. ...
... ALEXANDRIA, La., Sept. 18 Life Recovery ... an emerging provider of,groundbreaking medical devices for the ... System has been granted European CE,Mark (Conformite Europeene) ... e.g., to induce hypothermia in patients to,preserve cardiac ...
Cached Medicine Technology:Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 2Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 3Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 4Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System 2
Varicella-zoster virus (VZV) IgM Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the detection of IgM antibody to Varicella-zoster virus in human serum as an aid in the diagnosis of primar...
... Mumps IgG ELISA test system is intended ... antibody in human serum. When performed according ... test, together with other clinical information, may ... and/or aid in the diagnosis of Mumps ...
... IgG Enzyme-linked Immunosorbent Assay (ELISA) is intended ... IgG antibody to Mumps virus in human ... for the determination of immune status. Paired ... to demonstrate seroconversion or a significant rise ...
... system is comprised of the TEG analyzer and ... complete picture of the formation and dissolution of ... the two systems. ,Haemoscope's TEG analyzer is the ... follows the reliable and proven model developed by ...
Medicine Products: